首页> 外文OA文献 >A study to determine the maintenance of efficacy of agomelatine to prevent relapse in out-patients with major depressive disorder. A 8 to 10 weeks open period treatment with agomelatine followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period.

【2h】

A study to determine the maintenance of efficacy of agomelatine to prevent relapse in out-patients with major depressive disorder. A 8 to 10 weeks open period treatment with agomelatine followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period.

机译：一项研究，以确定治疗杂种碱疗效以防止患有重症抑郁症的患者复发。 AGOMELATINE的8至10周的开放期治疗，然后是24周随机化双盲期，安慰剂控制，平行组和20周的可选双盲治疗期。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Frederic Rouillon;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50 mg/day) and escitalopram (10-20 mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study [J] . Udristoiu T., Dehelean P., Nuss Ph, Journal of affective disorders . 2016,第Null期

机译：在患有严重抑郁症的门诊患者中，阿美美拉汀（25-50 mg /天）和依西酞普兰（10-20 mg /天）对一般人群的早期疗效以及短期抗抑郁药的疗效和安全性。一项为期12周的随机双盲比较研究
2. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. [J] . Goodwin GM, Emsley R, Rembry S The journal of clinical psychiatry . 2009,第8期

机译：阿戈美拉汀可预防重度抑郁症患者的复发而无终止综合征的证据：一项为期24周的随机，双盲，安慰剂对照试验。
3. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder. [J] . L Shu, A H Sulaiman, Y S Huang, Asian journal of psychiatry . 2014,第Null期

机译：亚洲重度抑郁症门诊患者使用阿美美拉汀25-50mg或氟西汀20-40mg治疗8周的疗效和安全性相当。
4. A Randomized, Double-Blind, Placebo-Controlled Crossover Trial Evaluating the Effect of Intranasal Insulin on Cognition and Emotional Processing in Individuals with Treatment-Resistant Major Depressive Disorder. [D] . Cha, Danielle Soh-Young. 2016

机译：一项随机，双盲，安慰剂对照的交叉试验评估了鼻内胰岛素对难治性重度抑郁症患者认知和情绪加工的影响。
5. Extended report: Ixekizumab an interleukin-17A specific monoclonal antibody for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised double-blind placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 [O] . Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, -1

机译：扩展报告：Ixekizumab一种白介素17A特异性单克隆抗体用于治疗初生性活动性银屑病关节炎患者：24周随机双盲安慰剂对照和活性（阿达木单抗）对照期的结果SPIRIT-P1 III期试验
6. Efficacy of agomelatine given orally on the quality of remission in elderly depressed patients, after a 12-week treatment period. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus SSRI drug. Twelve-week treatment plus optional continuation for 12 weeks. [O] . Thierry Bougerol 2013

机译：在治疗期为12周的治疗期后，在老年人抑郁症患者的缓解质量上口头上的疗效。随机，双盲，灵活的DOSE国际多期一组与平行组对SSRI药物进行。 12周治疗加上可选的延续12周。

著录项

引文网络

相似文献

相关主题

期刊订阅